Propanc Biopharma, Inc.
NASDAQ: PPCB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Nathanielsz
- Employees
- 1
- Headquarters
- Camberwell, Australia
- IPO year
- 2012
- Market cap
- $1.3M
- Website
- https://www.propanc.com
Loading PPCB…
Loading profile data…Frequently asked questions about PPCB
What does Propanc Biopharma, Inc. (PPCB) do?
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This pr...
Where does PPCB trade?
Propanc Biopharma, Inc. (PPCB) trades on the NASDAQ Capital Market.
What sector is PPCB in?
Propanc Biopharma, Inc. (PPCB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Propanc Biopharma, Inc.?
James Nathanielsz is the chief executive officer of Propanc Biopharma, Inc. (PPCB).
Where is Propanc Biopharma, Inc. headquartered?
Propanc Biopharma, Inc. is headquartered in Australia.
Does PPCB pay a dividend?
Propanc Biopharma, Inc. (PPCB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PPCB go public?
Propanc Biopharma, Inc. (PPCB) completed its initial public offering in 2012.